Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Seres Therapeutics (Nasdaq: MCRB) said management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025 at 10:30 a.m. ET. A live webcast will be accessible via the company’s Investors and News "Events and Presentations" page and will be available for replay after the event.
The presentation offers investors a real-time update opportunity and a post-event replay for later review.
Seres Therapeutics (Nasdaq: MCRB) ha comunicato che la direzione parteciperà a un incontro informale durante la 37th Annual Healthcare Conference di Piper Sandler il 2 dicembre 2025 alle 10:30 ET. Una trasmissione web in diretta sarà accessibile tramite la pagina di Investors and News "Events and Presentations" dell'azienda e sarà disponibile per la riproduzione dopo l'evento.
La presentazione offre agli investitori l'opportunità di aggiornamenti in tempo reale e una riproduzione post-evento per una revisione successiva.
Seres Therapeutics (Nasdaq: MCRB) dijo que la dirección participará en una charla junto a la chimenea en la Piper Sandler 37th Annual Healthcare Conference el 2 de diciembre de 2025 a las 10:30 a. m. ET. Una transmisión web en vivo estará disponible a través de la página de Investmenters and News "Events and Presentations" de la empresa y estará disponible para su reproducción después del evento.
La presentación ofrece a los inversionistas una oportunidad de actualización en tiempo real y una reproducción posterior para revisión.
Seres Therapeutics (Nasdaq: MCRB)의 경영진이 Piper Sandler 37th Annual Healthcare Conference에서 파이어사이드 채팅에 참여할 예정이라고 발표했습니다. 2025년 12월 2일 동부 표준시 10:30에 개최됩니다. 라이브 웹캐스트는 회사의 투자자 및 뉴스 "Events and Presentations" 페이지를 통해 접근 가능하며 행사 후 재생도 이용 가능합니다.
발표는 투자자들에게 실시간 업데이트 기회를 제공하고 행사 후 재생을 통해 후속 검토가 가능하도록 합니다.
Seres Therapeutics (Nasdaq : MCRB) a indiqué que la direction participera à une discussion informelle lors de la Piper Sandler 37th Annual Healthcare Conference le 2 décembre 2025 à 10 h 30 HE. Une diffusion en direct sera accessible via la page Investors and News "Events and Presentations" de l’entreprise et sera disponible en rediffusion après l’événement.
La présentation offre aux investisseurs une opportunité de mise à jour en temps réel et une rediffusion après l’événement pour révision.
Seres Therapeutics (Nasdaq: MCRB) sagte, dass das Management an einem Fireside-Chat beim Piper Sandler 37th Annual Healthcare Conference am 2. Dezember 2025 um 10:30 Uhr ET teilnehmen wird. Ein Live-Webcast wird über die Seite des Unternehmens unter Investors and News "Events and Presentations" zugänglich sein und nach der Veranstaltung als Wiedergabe verfügbar sein.
Die Präsentation bietet Investoren eine Echtzeit-Update-Gelegenheit und eine Wiedergabe nach der Veranstaltung zur späteren Überprüfung.
Seres Therapeutics (ناسداك: MCRB) قالت الإدارة إنها ستشارك في دردشة بجلسة fireside أثناء المؤتمر الصحي السنوي السابع والثلاثين لشركة بايبر ساندلر يوم 2 ديسمبر 2025 الساعة 10:30 صباحاً بالتوقيت الشرقي. سيكون هناك بث حي عبر صفحة الشركة للمستثمرين والأخبار "الأحداث والعروض" وسيكون متاحاً لإعادة العرض بعد الحدث.
تتيح العرضة للمستثمرين فرصة الحصول على تحديثات في الوقت الفعلي وإعادة العرض بعد الحدث للمراجعة لاحقاً.
- None.
- None.
CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:30 a.m. ET.
A live webcast of the chat will be accessible through the “Events and Presentations” tab on the “Investors and News” section of the Company’s website at http://www.serestherapeutics.com and will be available for replay following the event.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. Seres led the successful development and approval of VOWST™, the first FDA-approved orally administered microbiome therapeutic, which was sold to Nestlé Health Science in September 2024. The Company is developing SER-155, which has received Breakthrough Therapy designation for the reduction of bloodstream infections in adults undergoing allo-HSCT and Fast Track designation for reducing the risk of infection and graft-versus-host disease in adults undergoing allo-HSCT, and which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a Phase 1b clinical study in patients undergoing allo-HSCT. SER-155 and the Company's other pipeline programs are designed to target multiple disease-relevant pathways and are manufactured from standard clonal cell banks via cultivation, rather than from the donor-sourced production process used for VOWST. In addition to allo-HSCT, the Company intends to evaluate SER-155 and other cultivated live biotherapeutic candidates in other medically vulnerable patient populations including autologous-HSCT patients, cancer patients with neutropenia, CAR-T recipients, individuals with chronic liver disease, solid organ transplant recipients, as well as patients in the intensive care unit and long-term acute care facilities. For more information, please visit www.serestherapeutics.com.
Investor and Media Contact:
IR@serestherapeutics.com
Carlo Tanzi, Ph.D.
Kendall Investor Relations
ctanzi@kendallir.com
FAQ
When will Seres Therapeutics (MCRB) present at the Piper Sandler Healthcare Conference?
How can investors watch the Seres Therapeutics (MCRB) webcast for the December 2, 2025 presentation?
Will the Seres Therapeutics (MCRB) Piper Sandler presentation be available after the event?
What is the format of Seres Therapeutics (MCRB) participation at the Piper Sandler conference?
Where is the Piper Sandler 37th Annual Healthcare Conference presentation date for Seres Therapeutics (MCRB) listed?
